Synthetic RORγt Agonists Enhance Protective Immunity

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• RORγt is a key transcription factor for TH17 and TC17 cell differentiation.
• TH17 and TC17 cells exhibit antitumor efficacy by enhancing immunity and reducing immune suppression.
• RORγt agonists can increase TH17 cell proliferation.

Purpose of the Study:

• To investigate the effects of synthetic and endogenous RORγt agonists on TH17 cell proliferation and PD-1 levels.
• To explore the potential of RORγt agonists as a novel cancer treatment strategy.

Main Methods:

• Activation of RORγt using synthetic and putative endogenous agonists.
• Analysis of TH17 cell proliferation.
• Measurement of immune checkpoint protein PD-1 levels.
• Assessment of regulatory T cell (Treg) population.

Main Results:

• Synthetic RORγt agonists promote TH17 cell proliferation and decrease PD-1 levels, potentially enhancing anti-tumor immunity.
• Endogenous RORγt agonists promote TH17 cell proliferation but do not repress PD-1.
• Synthetic agonists may reduce Treg populations and induce IL17 production in situ.

Conclusions:

• Synthetic RORγt agonists offer a promising approach for cancer treatment by activating immune cells and downregulating immune checkpoints.
• The dual action of synthetic agonists (immune activation and checkpoint inhibition) presents a unique strategy against cancer.